The Role of Functional Magnetic Resonance Imaging in Preoperative Assessment of Primary Penile Carcinoma

Sponsor
Oslo University Hospital (Other)
Overall Status
Recruiting
CT.gov ID
NCT05447273
Collaborator
(none)
60
1
89.6
0.7

Study Details

Study Description

Brief Summary

The proposed project is intended as a prospective study that includes 60 patients with newly diagnosed penile squamous cell carcinoma (SCC) referred to Oslo University Hospital (OUH), Radiumhospitalet, for surgery, primarily organ-sparing surgery (OSS).

OSS may improve not only quality of life, but also quality of sexual function. However, there is a potential for increased risk of local recurrence after OSS compared to the amputation of the penis. Appropriate preoperative staging, including multi-parametric magnetic resonance imaging (mpMRI), can substantially improve selection of patients and decrease the recurrence rate after surgery.

MpMRI without artificial erection is promising diagnostic tool that is poised to be all-in-one solution for staging and preoperative assessment of primary penile cancer, especially prior to OSS. The method is non-invasive and thus comfortable to perform for most of the patients. Novel MRI techniques are not incorporated into current clinical recommendations, and the potential of new, functional sequences has not been evaluated before. The accuracy of functional, non-erectile mpMRI for detecting and staging of primary penile cancer is not known. Thus, the main purpose of this study is to assess the diagnostic value of this method for preoperative assessment of penile cancer.

Condition or Disease Intervention/Treatment Phase
  • Diagnostic Test: Multi-parametric, functional magnetic resonance imaging (MRI)

Study Design

Study Type:
Observational
Anticipated Enrollment :
60 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
The Role of Functional Magnetic Resonance Imaging in Preoperative Assessment of Primary Penile Carcinoma
Anticipated Study Start Date :
Jul 15, 2022
Anticipated Primary Completion Date :
Jun 1, 2024
Anticipated Study Completion Date :
Jan 1, 2030

Arms and Interventions

Arm Intervention/Treatment
Patients with penile squamous cell carcinoma.

Diagnostic Test: Multi-parametric, functional magnetic resonance imaging (MRI)
Multi-parametric, functional magnetic resonance imaging (MRI) will be performed in all included patients prior to surgery.

Outcome Measures

Primary Outcome Measures

  1. Functional imaging [2022-2024]

    Assess tumor extent and infiltration depth on multi-parametric MRI (mrT-stage) with histopathological evaluation as a reference standard. Explore usefulness of multi-parametric MRI in assessing inguinal and pelvic lymph nodes (mrN-stage). 2-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography (FDG PET-CT), sentinel lymph node evaluation and histopathological examination of the resected specimen will be a gold standard.

Secondary Outcome Measures

  1. Clinical outcome [2022-2030]

    Assess the locoregional recurrence rate and 5-year survival rate following OSS. Clinical outcome data will be obtained from 5 years clinical follow-up at the Department of Urology OUH.

  2. Functional outcome [2022-2030]

    Evaluation of urinary and sexual function following surgery. Functional outcome data will be assessed by urologists using a scoring system and according to the clinical practice, and from interviews with clinical sexologist.

Eligibility Criteria

Criteria

Ages Eligible for Study:
N/A and Older
Sexes Eligible for Study:
Male
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • newly diagnosed penile squamous cell carcinoma (SCC)

  • the patient will benefit from organ-sparing surgery (OSS)

  • signed broad consent for cancer research

Exclusion Criteria:
  • N/A

Contacts and Locations

Locations

Site City State Country Postal Code
1 Oslo University Hospital Oslo Norway

Sponsors and Collaborators

  • Oslo University Hospital

Investigators

  • Principal Investigator: Marta D Switlyk, MD PhD, Oslo University Hospital

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Marta Daniela Switlyk, Principal Investigator, Oslo University Hospital
ClinicalTrials.gov Identifier:
NCT05447273
Other Study ID Numbers:
  • 428797
First Posted:
Jul 7, 2022
Last Update Posted:
Jul 11, 2022
Last Verified:
Jul 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jul 11, 2022